Risedronic acid
Actonel, Atelvia, Risedronate (risedronic acid) is a small molecule pharmaceutical. Risedronic acid was first approved as Actonel on 1998-03-27. The pharmaceutical is active against farnesyl pyrophosphate synthase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Actonel, Atelvia, Risedronate (discontinued: Actonel, Risedronate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Risedronate sodium
Calcium carbonate
+
Risedronate sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ACTONEL WITH CALCIUM (COPACKAGED) | Warner Chilcott | N-021823 DISCN | 2005-08-12 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| actonel | New Drug Application | 2023-10-01 |
| atelvia | New Drug Application | 2023-10-20 |
| risedronate sodium | ANDA | 2025-04-02 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
ATC Codes
M: Musculo-skeletal system drugs
— M05: Drugs for treatment of bone diseases
— M05B: Drugs affecting bone structure and mineralization
— M05BA: Bisphosphonate drugs affecting bone structure and mineralization
— M05BA07: Risedronic acid
— M05BB: Bisphosphonates, combinations affecting bone structure and mineralization
— M05BB02: Risedronic acid and calcium, sequential
— M05BB04: Risedronic acid, calcium and colecalciferol, sequential
— M05BB07: Risedronic acid and colecalciferol
HCPCS
No data
Clinical
Clinical Trials
110 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 4 | 4 | 26 | 20 | 15 | 68 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 3 | 10 | 11 | 4 | 28 |
| Metabolic bone diseases | D001851 | — | — | 2 | 1 | 5 | 3 | 2 | 13 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 4 | 2 | 1 | 7 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 3 | 3 | 6 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 3 | 1 | — | 4 |
| Spinal fractures | D016103 | EFO_0003902 | S12 | — | — | 1 | 2 | 1 | 4 |
| Osteogenesis imperfecta | D010013 | — | Q78.0 | — | 1 | 1 | 1 | — | 3 |
| Osteoporotic fractures | D058866 | — | — | — | — | — | 1 | 2 | 3 |
| Fibrosis | D005355 | — | — | — | — | — | 1 | — | 1 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteitis deformans | D010001 | EFO_0004261 | M88 | — | — | 2 | — | 1 | 3 |
| Bone diseases | D001847 | — | M89.9 | — | — | 2 | — | — | 2 |
| Back pain | D001416 | — | M54 | — | — | 1 | — | 1 | 2 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | 1 | — | 1 | 2 |
| Anorexia | D000855 | — | R63.0 | — | 1 | 1 | — | 1 | 2 |
| Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | 1 | 1 | — | 1 | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | 2 | — | — | 2 |
| Myositis | D009220 | EFO_0000783 | G72.49 | — | — | 1 | — | — | 1 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | 1 | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postmenopause | D017698 | — | — | 1 | 2 | — | — | — | 3 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 1 | — | — | — | 1 |
| Spondylarthritis | D025241 | — | — | — | 1 | — | — | — | 1 |
| Spondylitis | D013166 | — | M46.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | 1 | 2 |
| Biological availability | D001682 | — | — | 1 | — | — | — | — | 1 |
| Infertility | D007246 | EFO_0000545 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Femoral fractures | D005264 | — | S72 | — | — | — | — | 2 | 2 |
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 1 | 1 |
| Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Adenocarcinoma | D000230 | — | — | — | — | — | — | 1 | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | — | — | — | 1 | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | — | — | 1 | 1 |
| Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Risedronic acid |
| INN | risedronic acid |
| Description | Risedronic acid is a member of pyridines. |
| Classification | Small molecule |
| Drug class | calcium metabolism regulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 105462-24-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL923 |
| ChEBI ID | 8869 |
| PubChem CID | 5245 |
| DrugBank | DB00884 |
| UNII ID | KM2Z91756Z (ChemIDplus, GSRS) |
Target
Agency Approved
FDPS
FDPS
Organism
Homo sapiens
Gene name
FDPS
Gene synonyms
FPS, KIAA1293
NCBI Gene ID
Protein name
farnesyl pyrophosphate synthase
Protein synonyms
(2E,6E)-farnesyl diphosphate synthase, Dimethylallyltranstransferase, Farnesyl diphosphate synthase, farnesyl pyrophosphate synthetase, dimethylallyltranstransferase, geranyltranstransferase, FPP synthase, FPP synthetase, Geranyltranstransferase
Uniprot ID
Mouse ortholog
Fdps (110196)
farnesyl pyrophosphate synthase (Q920E5)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Risedronic acid
+
Calcium carbonate
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Risedronic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,253 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
13,792 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use